Context Therapeutics Inc.

NASDAQ•CNTX

CEO: Mr. Martin A. Lehr

セクター: Healthcare

業種: Biotechnology

上場日: 2021-10-20

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

連絡先情報

2001 Market Street, Suite 3915 Unit #15, Philadelphia, PA, 19103, United States

(267)-225-7416

www.contexttherapeutics.com

時価総額

$262.77M

PER (TTM)

-10.3

17.2

配当利回り

52週高値

$3.62

52週安値

$0.49

52週レンジ

76%

順位63Top 94.0%

1.8

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 1.8 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.10-54.55%

直近4四半期の推移

フリーCF

-$6.58M+239.00%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Quarterly Net Loss Reduced Net loss narrowed to $(9.69)M for Q3 2025, significantly down 44% from $(17.46)M loss reported in Q3 2024.

R&D Spending Decreased Q3 Research and development expenses dropped $8.10M (48%) to $8.72M in 2025, reflecting lower CT-202 consideration payments.

Cash Runway Extended Cash and equivalents stood at $76.94M as of September 30, 2025, sufficient to fund projected operations into 2027.

Pipeline Milestones Achieved Dosed first patients for CTIM-76 (Jan 2025) and CT-95 (Apr 2025); CT-202 first-in-human filing expected Q2 2026.

リスク要因

Substantial Future Funding Needed Company requires substantial additional capital to fund operations and commercial development; no committed credit facility exists.

Intellectual Property Litigation Risk Third parties may assert infringement claims regarding CTIM-76 IP, potentially blocking development or requiring costly licensing agreements.

Regulatory Approval Uncertainty Delays or changes in FDA requirements for CTIM-76, CT-95, or CT-202 approval processes could materially affect operations.

Negative Cash Flow Continues Nine months cash used in operations totaled $(17.44)M; no product revenue generated since inception.

見通し

Upcoming Clinical Data Readouts Expect updated interim Phase 1a data for CTIM-76 in Q2 2026 and initial Phase 1a data for CT-95 mid-2026.

CT-202 First-in-Human Trial Plan to complete necessary regulatory filings to support initiation of the first-in-human trial for CT-202 in Q2 2026.

Financing Strategy Remains Active Management plans to seek capital via equity offerings, debt financings, or collaborations to support ongoing development activities.

Post-Period Milestone Payment Achieved $2.0M development milestone for CT-202 in October 2025, expected to be paid in the fourth quarter of 2025.

同業比較

売上高 (TTM)

MGNX

$149.50M

+0.8%

AGEN

$106.83M

-33.4%

SEER

$16.58M

+18.2%

粗利益率 (最新四半期)

OVID

87.1%

-12.9pp

TCRX

71.8%

-30.5pp

ARMP

68.1%

-21.4pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ARMP	$349.87M	-7.4	70.3%	198.5%
NAUT	$335.39M	-5.7	-33.6%	15.7%
CNTX	$262.77M	-10.3	-30.9%	0.2%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日

EPS:-$0.11

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし